Elevation Oncology company information, Employees & Contact Information

Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right PR Newswire

Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options PR Newswire

Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements PR Newswire

Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates PR Newswire

Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference Stock Titan

Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025 PR Newswire

Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025 PR Newswire

Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones PR Newswire

Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors PR Newswire

Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements PR Newswire

Elevation Oncology Emerges from Stealth with $32.5M Series A to Develop Precision Medicines for Tumors Harboring Rare Genetic Driver Alterations PR Newswire

Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2 PR Newswire

Elevation Oncology Announces Pricing of $50 Million Public Offering PR Newswire

Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group PR Newswire

Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer PR Newswire

Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors PR Newswire

Elevation Oncology Announces Pricing of Initial Public Offering PR Newswire

Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer PR Newswire

Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer PR Newswire

Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023 PR Newswire

Elevation Oncology Announces the Promotion of Valerie Malyvanh Jansen, M.D., Ph.D., to Chief Medical Officer PR Newswire

FDA Grants Fast Track Status to EO-3021 for CLDN18.2-Expressing Gastric or GEJ Cancer OncLive

Elevation Oncology Halts Cancer Drug Development, Slashes Jobs in Major Strategic Shift Stock Titan

Elevation Oncology Appoints Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors citybiz

Concentra to acquire Elevation in bid to eliminate another biotech ‘zombie’ BioPharma Dive

Elevation Oncology and US Oncology Research Announce Collaboration to Expand Genomic Testing of Solid Tumors and Local Site Activation in Support of the Phase 2 CRESTONE Study PR Newswire

Elevation Oncology Plunges 42% on Ending Development of Lead Drug Yahoo Finance

Why Elevation Oncology (ELEV) Is Among the Best Penny Stocks to Invest In According to Media? Yahoo Finance

Elevation Oncology agrees to be acquired by Concentra The Pharma Letter

Elevation drops sole clinical-stage ADC over poor phase 1 data, lays off 70% of staff Fierce Biotech

What Makes Elevation Oncology (ELEV) a New Strong Buy Stock Yahoo Finance

Elevation Oncology Completes Merger with Concentra Biosciences TipRanks

Elevation Oncology to Participate at Cowen's 3rd Annual Oncology Innovation Summit MarketScreener

Elevation Oncology to Participate at Upcoming Virtual Investor Conferences MarketScreener

Elevation Oncology : to Present at the H.C. Wainwright 23rd Annual Global Investment Conference MarketScreener

Elevation Oncology sets out for clinic climb in $27M licensing deal for CSPC's ADC Fierce Biotech